Principal Director, Martin Robinson Joins ACRES Steering Committee
The International Academy of Clinical Research (IAoCR) has become a member of the Alliance for Clinical Research Excellence and Safety (ACRES) it was announced today in a joint statement from Dr. Greg Koski, President and CEO of ACRES and Dr. Martin Robinson, Principal Director and Co-Founder of the IAoCR. Dr. Robinson has also been appointed to the ACRES Global Steering Committee.
Sharing many common goals with the IAoCR, ACRES, a non-profit organisation based in Cambridge, Massachusetts, is committed to building a comprehensive, sustainable and shareable system for clinical research professionals across the globe. By bringing together expert stakeholders, ACRES’s goal is to create effective solutions that ensure safety, data quality and integrity in an efficient, collaborative and cost effective manner to improve the health and lives of people everywhere.
Commenting on this collaboration, Robinson says, “There is a great synergy between our organisations and working together we will look to develop and implement a comprehensive global system of best practices in accreditation, certification and education in clinical research. On a more personal note, I feel privileged to have been invited to sit on the ACRES Global Steering Committee and look forward to working with such an esteemed group of industry experts.”
Koski adds, “As a member of ACRES Global Steering Committee, Dr. Robinson will bring key insights from his experience with competency-based education and training of professional members of the clinical research team as well as with certification as criteria for accreditation.”
ACRES Global Steering Committee members are executives/senior managers from the biomedical research enterprise's stakeholders and/or subject matter specialists, providing advice and guidance to ACRES Board of Directors and the Executive Office.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.